Press Release: Cardialen : Cardialen Announces Positive Results from Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation

MINNEAPOLIS--(BUSINESS WIRE)-- #bioscience--Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation. The study consisted of 42 patients who were indicated for AF ablation. In the efficacy portion of the study, MPT achieved 71% termination of AF episodes at energy levels deemed to be tolerable for patients (interquartile range of 0.14 to 1.21 Joules). Dr.